Introduction
============

In chronic obstructive pulmonary disease (COPD) carbon monoxide uptake in the lung (DL~CO~) is determined to assess the associated presence of emphysema ([@b17-copd-1-477]). Reduction of the parameter is deemed to be due to functional and/or anatomical reductions of the alveolar and capillary surfaces available for gas exchange ([@b16-copd-1-477]; [@b5-copd-1-477]; [@b20-copd-1-477]). For bronchodilator therapy may improve lung volume recruitment as a result of a decrease in RV in both chronic obstructive bronchitis and emphysema ([@b7-copd-1-477]), and thus increase the amount of gas inhaled with a single inspiration, it would be reasonable to expect an increase in DL~CO~ in COPD after bronchodilatation. However, the few studies conducted in this regard gave contrasting results. Two studies demonstrated that at least for diagnostic purposes, the test may be safely performed either before or after dilator agonists ([@b15-copd-1-477]; [@b8-copd-1-477]), whereas a study showed a significant increase in DL~CO~ with inhaled terbutaline 1.5 mg ([@b2-copd-1-477]). Part of these discrepancies could be explained by the different degree of bronchodilatation achieved with different pharmacological agents and/or the variable association of emphysema with chronic obstructive bronchitis in COPD, both possibly affecting the DL~CO~ measurement as a result of different lung volume and pulmonary vascular bed recruitment.

Gaining information on the effects of the bronchodilator agents on the test is clinically relevant as DL~CO~ is a functional marker of the progression of a disease treated with different therapeutic protocols and doses of beta-2 agonists. Indeed, the variable course of the disease and/or the chronic effects of bronchodilator therapy may lead to recruitment of alveolar volume within lung regions previously served by closed or near-closed airways and/or improvement of blood perfusion across the lung over time, thus potentially affecting the DL~CO~ and its interpretation.

On this ground, we wondered whether DL~CO~ varies with the degree of pharmacologically-induced bronchodilatation and/or extent of emphysema in COPD.

To test this hypothesis, we studied lung function and diffusing capacity before and after cumulative doses of inhaled salbutamol. The study was conducted in a group of 21 COPD patients well characterized for degree of emphysema, as assessed by radiological criteria.

Methods
=======

Patients
--------

Eighteen male and tree female patients affected by COPD, as defined by the international guidelines ([@b17-copd-1-477]) participated in the study ([Table 1](#t1-copd-1-477){ref-type="table"}). Six of them were current smokers and fifteen former smokers, with an average smoking history of 51.6 ± 18.8 pack-years. Airflow obstruction ranged from moderately severe to very severe. All patients were required to abstain from short-acting bronchodilators for at least 12 h prior to each study session, to be in stable clinical conditions, and not to have suffered from respiratory exacerbation in the previous four weeks. The Ethics Committee approved the experimental protocol, and a written informed consent was obtained prior to the study from each subject.

Study design
------------

The patients attended the laboratory in the morning of two separate days. On the first day, absolute lung volumes, DL~CO~, and partial (PEFV) and maximal (MEFV) flow-volume curves were measured at baseline (Step 1). The same measurements were repeated in the same order 15 min after each of the following sequential doses of salbutamol given through a spacer by metered dose inhaler: 200 μg (Step 2), 400 μg (Step 3), and 400μg (Step 4). The doses were chosen to cover at least part of the broad range of bronchodilator responses reported in COPD ([@b3-copd-1-477]; [@b6-copd-1-477]). On the second day, a high resolution computed tomography (HRCT) of the lung was obtained.

Lung function measurements
--------------------------

Inspired and expired volumes were obtained by numerical integration of mouth flow measured by a mass flow sensor (Sensor Medics, Yorba Linda, CA). After at least 8 regular tidal breaths, the patients were asked to expire forcefully from about 60% of vital capacity (VC) to residual volume (RV) (PEFV maneuver), to rapidly inspire to total lung capacity (TLC), and forcefully expire to RV (MEFV maneuver) without breath hold. The latter allowed the forced expiratory volume in one second (FEV~1~) and forced vital capacity (FVC) to be computed. At least three technically acceptable curves were recorded. Flows at 30% of control FVC were taken on MEFV (Vmax~30~) and PEFV (Vpart~30~) curves.

Lung volumes were measured with the patients sitting in a body plethysmograph (Jaeger Masterlab, Jaeger, Würzburg, Germany) and panting against a closed shutter at a frequency slightly \<1 Hz, cheeks supported by hands. TLC was obtained as the sum of thoracic gas volume (TGV) and the linked inspiratory capacity. Functional residual capacity (FRC) was obtained from TGV corrected for any difference between the volume at which the shutter was closed and the average end-expiratory volume of the four preceding regular tidal breaths. RV was the difference between TLC and VC. Predicted values for spirometry and lung volume are from Quanjer and colleagues (1979).

DL~CO~ was measured according to the American Thoracic Society (ATS) recommendations ([@b11-copd-1-477]) with a Baires System (Biomedin, Padua, Italy), using a gas mixture of 0.3% CO, 10% helium, and balance air. Breath holding time was measured by the method of Jones-Meade ([@b15-copd-1-477]). At each step of the study, two measurements of DL~CO~ were made at a 4-min interval and were accepted if their inspired volumes were within 0.2 L between each other and 10% of the VC measured by spirometry. Adjustment for carboxyhemoglobin (HbCO) to account for the effect of increasing CO concentrations, and adjustment for Hb concentrations with repeated DL~CO~ measurements were done according to the ATS statement ([@b1-copd-1-477]) in 10 patients who had their arterial blood drawn at the four steps of the study. In the other 11 patients, DL~CO~ was corrected for the average slope of the linear regression analysis of DL~CO~ adjusted versus nonadjusted for HbCO in the 10 patients. Reference values for DL~CO~ are from [@b10-copd-1-477].

Imaging
-------

Lung HRCT was performed with a third-generation, continuous-rotation-computerized tomograph with single scan acquisition (Somaton Plus, Siemens, Erlangen, Germany). Technical parameters were the following: 1mm collimation, 137 kVp, 195 mAs, and \<1s scanning time. The lungs were scanned from the apex through the base at 1cm intervals and reconstructed with a lung algorithm.

All scan images were processed off-line using a semiautomated image-processing program, which extracts boundaries of the lungs, calculates lung cross sectional areas and histograms of attenuation values (CT numbers) of individual highlighted sections, and summarizes data to obtain the frequency distribution of attenuation values for both lungs. From the frequency distribution of CT numbers, mean CT number in Hounsfield units (HU) were derived. Percent of the whole lung area with attenuation values lower than −950 HU (RA~950~) was taken as an index of extent of emphysema ([@b13-copd-1-477], [@b14-copd-1-477]).

Statistical analysis
--------------------

Data are expressed as mean ± standard deviation. Relationships between variables were tested by linear regression analysis. Analysis of variance (ANOVA) for repeated measures was used to compare the effects of increasing doses of salbutamol at the different steps. When F values were significant, Tukey's post hoc test was used for multiple comparisons. P \< 0.05 was considered statistically significant.

Results
=======

The severity of airway obstruction, based on spirometric data, ranged from moderate to very severe ([Table 1](#t1-copd-1-477){ref-type="table"}). Emphysema was variably present, as suggested by the wide ranges of RA~950~, lung hyperinflation and DL~CO~ ([Table 1](#t1-copd-1-477){ref-type="table"}).

Seventeen patients completed the four steps of study, and four asked to interrupt the test at step 3 after a cumulative dose of 600 μg. Increasing the dose of salbutamol caused a progressive and significant increase in Vmax~30~, V part~30~, FEV~1~, and FVC, and a decrease in FRC and RV, consistent with effective bronchodilatation and decrease in lung hyperinflation ([Table 2](#t2-copd-1-477){ref-type="table"}). Average DL~CO~ progressively increased with bronchodilatation, but this became significant only with the highest dose of salbutamol (p \< 0.05) ([Table 2](#t2-copd-1-477){ref-type="table"}). In contrast, no significant changes occurred in V~A~ and DL~CO~/V~A~ ([Table 2](#t2-copd-1-477){ref-type="table"}).

The slopes of linear regression analysis of DL~CO~ plotted against FEV~1~, VC, and FRC at the four steps in individual patients were significantly different from 0 ([Table 3](#t3-copd-1-477){ref-type="table"} and [Figure 1](#f1-copd-1-477){ref-type="fig"}), thus suggesting that DL~CO~ tended to increase with bronchodilatation and volume recruitment. In contrast, only the slope of the linear regression of DL~CO~/V~A~ versus FEV~1~attained statistical significance ([Table 3](#t3-copd-1-477){ref-type="table"}).

Neither of these slopes correlated with the extent of emphysema as assessed by HRCT scan, thus suggesting that DL~CO~ increased with bronchodilatation irrespective of the extent of emphysema, as assessed with imaging techniques ([Figure 2](#f2-copd-1-477){ref-type="fig"}).

DL~CO~ % pred correlated with the extent of emphysema at all 4 steps of the study ([Figure 3](#f3-copd-1-477){ref-type="fig"}).

Discussion
==========

The major findings of the present study on COPD patients are that DL~CO~ progressively increased with cumulative doses of inhaled salbutamol to become significant at doses higher than those commonly used for clinical treatments. In addition, this occurred independently of the presence and extent of emphysema, as assessed by radiological parameters. V~A~ tended to increase, so that DL~CO~/V~A~ remained unchanged.

Theory predicts that VA, permeability characteristics of the alveolar-to-capillary barrier, and ability of hemoglobin to combine with CO are the main determinants of DL~CO~ ([@b16-copd-1-477]; [@b5-copd-1-477]; [@b8-copd-1-477]). Therefore, any intervention resulting in recruitment of lung volume would be expected to increase DL~CO~. Unexpectedly however, the substantial increase in slow VC observed with salbutamol in our COPD patients was not associated with a significant increase in DL~CO~. The increment in VC was due to a decrease in RV and not to an increase in TLC, which suggests opening of airways previously closed. Had the lack of increase in DL~CO~ mostly manifested in patients with low lung elastic recoil as in emphysema despite the decrease in RV, this would have been presumably the result of opening of airways subtending enlarged emphysematous units with disrupted vascular component unable to subtract CO from the alveoli. The absence of any relationship between changes in DL~CO~ and DL~CO~/V~A~ after salbutamol and HRCT data suggests, therefore, additional and/or alternative mechanisms. Among them is the possibility that VA was already fully recruited at maximal inflation even before inhaling the bronchodilator. Under these conditions, the effects of the medication on bronchial tone were negligible to recruit new V~A~ useful for gas exchange. Alternatively, alveolar recruitment with salbutamol in COPD occurred in the airways subtending alveolar units with hypoxic vasoconstriction. As documented in many animal species including humans, a decrease in O~2~ tension in the alveolar compartment would cause a local increase in pulmonary vascular resistance, as a result of narrowing of pre-capillary arteries by mechanisms involving K^+^ and Ca^++^ channels ([@b18-copd-1-477]) and enhanced by local acidosis ([@b12-copd-1-477]). With bronchodilatation and ensuing alveolar recruitment, hypoxic vasoconstriction might have disappeared and DL~CO~ increased, unless vascular reopening lagged behind alveolar reopening.

An additional cause for an increased DL~CO~ with high doses of salbutamol might have been the increase in cardiac output and the resulting distension of the pulmonary bed. Though we do not bring direct evidence for this, the increase in heart rate reported in healthy volunteers after doses of salbutamol similar to ours ([@b4-copd-1-477]) would suggest that the cardiovascular side-effects of high doses of β~2~ agonists might be indeed capable of increasing cardiac output, thus possibly contributing to increase DL~CO~. Yet, it remains to demonstrate that these doses of salbutamol can really do that.

Previous studies have documented that imposing an inspiratory resistance in healthy subjects is associated with an increase in DL~CO~, as a result of an increase in pleural pressure and ensuing amount of blood shifted from the abdomen to the chest wall and lungs ([@b9-copd-1-477]; [@b21-copd-1-477]). By converse, a decreased inspiratory resistance would be expected to lower DL~CO~. Whether the bronchodilatation observed in the present study might have affected DL~CO~ is a matter of speculation, though it could have also contributed to blunt the expected increase in DL~CO~.

The fact that DL~CO~ increased with progressive reduction in bronchial tone may have some clinical relevance. For instance, in clinical trials using this parameter as a functional outcome for follow-up or evaluation of the effects of new, nonbronchodilator treatments in emphysema, any significant change of DL~CO~ should be taken with cautiousness before concluding that this reflects a clear disease modification. In contrast, the maintenance of the correlation between DL~CO~ as % pred and extent of emphysema ([Figure 3](#f3-copd-1-477){ref-type="fig"}) at all 4 steps would apparently suggest that the effect of bronchial tone on DL~CO~ is insignificant with respect to the diagnosis of the disease.

In conclusion, the present study documents that improved lung function induced with cumulative doses of inhaled salbutamol is associated with a slight but significant increase in DL~CO~ irrespective of the presence and extent of emphysema. These findings implicate that changes in DL~CO~ over time, as observed in clinical or therapeutic trials, may be at least in part affected by changes in airway caliber.

![Linear regression lines of DL~CO~ versus FEV~1~ with incremental doses of salbutamol in individual patients. Values are expressed as % of predicted.\
**Abbreviations:** DL~CO~, carbon monoxide diffusing capacity; FEV~1~, forced expiratory volume in one second.](copd-1-477f1){#f1-copd-1-477}

![Relationships between linear regression slopes of DL~CO~ versus FEV~1~ with increasing doses of salbutamol and extent of emphysema, as assessed by HRCT scan quantitative analysis (RA~950~).\
**Abbreviations:** DL~CO~, carbon monoxide diffusing capacity; FEV~1~, forced expiratory volume in one second; HU, Hounsfield units; RA~950~, lung area with attenuation values lower than −950 HU.](copd-1-477f2){#f2-copd-1-477}

![Relationships between DL~CO~ as % of predicted and extent of emphysema, as assessed by HRCT scan quantitative analysis (RA~950~), at the four steps of the study.\
**Abbreviations:** DL~CO~, carbon monoxide diffusing capacity; HRCT, high resolution computed tomography; HU, Hounsfield units; RA~950~, lung area with attenuation values lower than −950 HU.](copd-1-477f3){#f3-copd-1-477}

###### 

Main anthropometric, functional, and imaging data

                         Mean ± SD   Range
  ---------------------- ----------- ----------
  Age, yr                69 ± 8      54--84
  BMI, Kg/m^2^           27 ± 4      19--34
  FEV~1~, % pred         45 ± 16     19--69
  VC, % pred             76 ± 19     40--123
  FRC, % pred            156 ± 32    104--223
  RV, % pred             176 ± 49    120--288
  TLC, % pred            112 ± 14    93--145
  DL~CO~, % pred         57 ± 23     24--105
  DL~CO~/V ~A~, % pred   50 ± 19     21--108
  PaCO~2~, mmHg          37 ± 4      27--44
  PaO~2~, mmHg           66 ± 8      52--76
  Hb, g/dl               14 ± 2      12--17
  RA~950~, %             19 ± 7      6--31

**Notes:** Data are means ± SD.

**Abbreviations:** BMI, body mass index; DL~CO~, carbon monoxide diffusing capacity; FEV~1~, forced expiratory volume in one second; FRC, functional residual capacity; RV, residual volume; SD, standard deviation; TLC, total lung capacity; VC, vital capacity; V~A~, alveolar volume; PaCO~2~, arterial carbon dioxide tension; PaO~2~, arterial oxygen tension; Hb, hemoglobin; RA~950~, lung area with attenuation values lower than −950 HU.

###### 

Main respiratory functional parameters at baseline and after additional doses of salbutamol

                                                      STEP 1 Baseline   STEP 2 200 μg                                           STEP 3 600 μg                                           STEP 4 1000 μg
  --------------------------------------------------- ----------------- ------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------
  Subjects, no.                                       21                21                                                      21                                                      17
  FEV~1~, L                                           1.14 ± 0.40       1.26 ± 0.43[c](#tfn5-copd-1-477){ref-type="table-fn"}   1.32 ± 0.45[c](#tfn5-copd-1-477){ref-type="table-fn"}   1.42 ± 0.50[c](#tfn5-copd-1-477){ref-type="table-fn"}
  FVC, L                                              2.55 ± 0.88       2.83 ± 0.93[c](#tfn5-copd-1-477){ref-type="table-fn"}   2.97 ± 0.97[c](#tfn5-copd-1-477){ref-type="table-fn"}   3.02 ± 1.03[c](#tfn5-copd-1-477){ref-type="table-fn"}
  V˙max~30~, L/s                                      0.24 ± 0.15       0.29 ± 0.21                                             0.35 ± 0.27[c](#tfn5-copd-1-477){ref-type="table-fn"}   0.36 ± 0.24[c](#tfn5-copd-1-477){ref-type="table-fn"}
  V˙part~30~, L/s                                     0.42 ± 0.21       0.51 ± 0.24                                             0.54 ± 0.29[c](#tfn5-copd-1-477){ref-type="table-fn"}   0.57 ± 0.28[c](#tfn5-copd-1-477){ref-type="table-fn"}
  VC, L                                               2.65 ± 0.85       2.98 ± 0.89[c](#tfn5-copd-1-477){ref-type="table-fn"}   3.14 ± 0.97[c](#tfn5-copd-1-477){ref-type="table-fn"}   3.36 ± 1.08[c](#tfn5-copd-1-477){ref-type="table-fn"}
  FRC, L                                              5.28 ± 1.42       5.02 ± 1.40[c](#tfn5-copd-1-477){ref-type="table-fn"}   4.85 ± 1.34[c](#tfn5-copd-1-477){ref-type="table-fn"}   4.72±1.30[c](#tfn5-copd-1-477){ref-type="table-fn"}
  RV, L                                               4.22 ± 1.35       3.96 ± 1.31[c](#tfn5-copd-1-477){ref-type="table-fn"}   3.82 ± 1.32[c](#tfn5-copd-1-477){ref-type="table-fn"}   3.59 ± 1.35[c](#tfn5-copd-1-477){ref-type="table-fn"}
  TLC, L                                              6.92 ± 1.54       6.94 ± 1.57                                             6.95 ± 1.57                                             6.97 ± 1.50
  HbCO[a](#tfn3-copd-1-477){ref-type="table-fn"}, %   2.3 ± 0.6         3.3 ± 0.6[c](#tfn5-copd-1-477){ref-type="table-fn"}     4.3 ± 0.6[c](#tfn5-copd-1-477){ref-type="table-fn"}     5.2 ± 0.7[c](#tfn5-copd-1-477){ref-type="table-fn"}
  V~A~, L                                             4.93 ± 1.00       5.17 ± 1.06                                             5.05 ± 1.03                                             5.15 ± 1.07
  DL~CO~, ml/mmHg/min/L                               14.35 ± 5.07      15.12 ± 4.81                                            15.72 ± 4.95                                            16.41 ± 5.02[b](#tfn4-copd-1-477){ref-type="table-fn"}
  DL~CO~/V ~A~, ml/mmHg/min/L                         3.03 ± 1.20       3.07 ± 1.17                                             3.21 ± 1.08                                             3.23 ± 1.06

**Note:** HbCO, carboxyhemoglobin measured in 10 patients;

p \< 0.05;

p \< 0.01 or less versus baseline; Data are means ± SD.

**Abbreviations:** DL~CO~, carbon monoxide diffusing capacity; FEV~1~, forced expiratory volume in one second; FRC, functional residual capacity; FVC, forced vital capacity; RV, residual volume; SD, standard deviation; TLC, total lung capacity; V˙max~30~ and V˙part~30~, maximal and partial forced expiratory flows at 30% control FVC; V~A~, alveolar volume; VC, vital capacity.

###### 

Average linear regression slopes of DL~CO~, and DL~CO~/V~A~ versus key variables with inhalation of increasing doses of salbutamol.

  Variables    DL~CO~                                                  DL~CO~/V~A~
  ------------ ------------------------------------------------------- -----------------------------------------------------
  FEV~1~       11.8 ± 14.0[b](#tfn9-copd-1-477){ref-type="table-fn"}   3.6 ± 5.8[a](#tfn8-copd-1-477){ref-type="table-fn"}
  FVC          1.1 ± 11.6                                              0.01 ± 4.0
  V˙max~30~    4.3 ± 25.2                                              1.9 ± 6.6
  V˙part~30~   12.3 ± 35.3                                             1.8 ± 8.1
  VC           3.9 ± 6.0[b](#tfn9-copd-1-477){ref-type="table-fn"}     1.0 ± 2.6
  FRC          −3.9 ± 8.1[a](#tfn8-copd-1-477){ref-type="table-fn"}    −0.6 ± 2.4

**Notes:** Data are means ± SD; Significant differences from baseline conditions are denoted with symbols:

p \< 0.05;

p \< 0.01 or less.

**Abbreviations:** DL~CO~, carbon monoxide diffusing capacity; FEV~1~, forced expiratory volume in one second; FRC, functional residual capacity; FVC, forced vital capacity; SD, standard deviation; V˙max~30~ and V˙part~30~, maximal and forced expiratory flows at 30% control FVC; V~A~, alveolar volume; VC, vital capacity.
